Want to join the conversation?
Therapeutic products maker $ANIK said the US FDA Office of Combination Products has allotted CINGAL, used to treat joint pain due to osteoarthritis, to the Center for Drug Evaluation and Research as the lead center for premarket review. Though $ANIK disagrees with FDA's decision, it intends to move swiftly to take CINGAL through regulatory review.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th
Wow! $MCD scores again.
$SPY can the rally continue? La Pen almost assured to lose makes me cautious about the results, not a place to panic. If 2400 is reached I'm selling my puts and going for broke. Happy hunting.